Key result
Reperfusion therapy linked to ~95% lower 90-day mortality in intermediate-high and high-risk PE.
Why the study?
Intermediate-high and high-risk PE carry substantial mortality despite anticoagulation, but real-world evidence comparing treatment strategies and identifying mid-term mortality predictors remains limited.
Does reperfusion therapy reduce all-cause 90-day mortality in patients with intermediate-high and high-risk acute pulmonary embolism?
Population
114 consecutive patients with intermediate-high or high-risk acute PE at a tertiary referral center
Comparison
Reperfusion therapy vs anticoagulation alone
Design
Retrospective cohort study
Follow-up
90 days
Authors
Loading...
Supports reperfusion consideration in intermediate-high/high-risk PE; leaves open confirmation by randomized trials.
Cohort (n=114)
No
Does reperfusion therapy reduce all-cause 90-day mortality in patients with intermediate-high and high-risk acute pulmonary embolism?
Odds Ratio: 0.05 (95% CI 0.003–0.65)
p-value: p=0.022
In a real-world cohort of intermediate-high and high-risk PE, reperfusion therapy was associated with significantly lower 90-day mortality compared to anticoagulation alone.
Batum et al. (2026) conducted a cohort in Intermediate-high and high-risk acute pulmonary embolism (n=114). Reperfusion therapy (systemic thrombolysis or catheter-directed therapy) vs. Anticoagulation alone was evaluated on All-cause 90-day mortality (OR 0.05, 95% CI 0.003-0.65, p=0.022). Reperfusion therapy was independently associated with a significant reduction in 90-day mortality in intermediate-high and high-risk pulmonary embolism (OR 0.05; 95% CI 0.003-0.65; p=0.022).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: